Brolucizumab in Neovascular Age-Related Macular Degeneration – Indian Real-World Experience: The BRAILLE Study
Open Access
- 1 September 2021
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 15, 3787-3795
Abstract
Purpose: To assess the short-term efficacy and safety profile of intravitreal brolucizumab injection in Indian eyes with neovascular age-related macular degeneration (nAMD) under real-world conditions. Patients and Methods: This was a multicenter, retrospective chart review of 94 eyes of 94 patients with nAMD (treatment-naïve and switch-therapy) undergoing brolucizumab therapy. Re-treatment as per pro-re-nata protocol was performed based on fixed visual and tomographic criteria. The main outcome measures were changes in the best-corrected visual acuity (BCVA), intraretinal fluid (IRF), subretinal fluid (SRF), central subfield thickness (CST), and pigment epithelial detachment (PED) along with safety analysis. Results: Of the 94 eyes, 20 eyes (21.3%) were treatment-naïve, whereas the rest 74 eyes (78.7%) underwent switch therapy. One hundred and twenty-six injections were given over a mean follow-up of 7.3 ± 2.2 (range 5– 30) weeks. The BCVA improved significantly from 0.82 ± 0.5 LogMAR at baseline to 0.66 ± 0.5 LogMAR at the final visit (p < 0.0001). Significant reduction in CST was simultaneously noted (Baseline: 408.45 ± 65.63 μm; Final: 281.14 ± 37.74 μm; p < 0.0001). On qualitative analysis, resolution of subretinal fluid (SRF), intraretinal fluid (IRF), and pigment epithelial detachment (PED) was observed in 15.5%, 39.29%, and 23.81% of the eyes, respectively. The mean interval of repeat injection was 10.2 ± 2.1 weeks. Three episodes of ocular adverse drug reaction were reported, including two patients developing subretinal hemorrhage while one having a retinal pigment epithelial (RPE) tear. Notably, no intraocular inflammation (IOI) was seen in any of the eyes, and no systemic side effects were identified. Conclusion: In a real-world scenario, brolucizumab therapy is efficacious and safe in the management of nAMD over the short term. Further long-term studies are warranted to validate these findings. Additionally, lack of ocular inflammation after 126 brolucizumab injections in our Indian data is peculiar and underlines the necessity to explore the role of race and genetics in predisposing to/safeguarding against brolucizumab-related IOIs.Keywords
This publication has 28 references indexed in Scilit:
- Safety Assessment and Power Analyses in Published Anti–Vascular Endothelial Growth Factor Randomized Controlled TrialsAmerican Journal of Ophthalmology, 2016
- Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degenerationCochrane Database of Systematic Reviews, 2016
- Anti-VEGF Therapy for Retinal Vein OcclusionsCurrent Drug Targets, 2016
- The Association of Race With Childhood UveitisAmerican Journal of Ophthalmology, 2015
- The Impact of Anti–Vascular Endothelial Growth Factor Treatment on Quality of Life in Neovascular Age-Related Macular DegenerationOphthalmology, 2014
- The Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab InjectionsOphthalmology, 2014
- Vitreous Inflammation Associated with Intravitreal Anti-VEGF PharmacotherapyMediators of Inflammation, 2013
- Incidence and Prevalence of UveitisJAMA Ophthalmology, 2013
- Ocular and systemic safety of bevacizumab and ranibizumab in patients with neovascular age-related macular degenerationCurrent Opinion in Ophthalmology, 2013
- Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on afliberceptClinical Ophthalmology, 2012